International Journal of Clinical Reviews

Advanced search

Latest Articles

• Axitinib: A Next Generation VEGFR inhibitor for Metastatic Renal Cell Cancer

  Rob Zielinski, MBBS, and Christian Kollmannsberger, MD

  British Columbia Cancer Agency, Vancouver, BC, Canada
  
  Pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) and its receptors, are important regulators of tumor angiogenesis, survival, and metastasis, and are overexpressed in renal cell carcinoma (RCC). There is a plethora of US Food and Drug Administration (FDA)-approved agents for advanced RCC that inhibit circulating VEGF or its targets, the VEGF-receptors (VEGFRs).

  » Read more

  Categories: Oncology, Urology

  Riluzole and Amyotrophic Lateral Sclerosis

  Luc Dupuis, PhD^1,2,3,4, Albert C Ludolph MD³, and Vincent Meininger MD^4,5

  ¹Inserm U692; ²Université de Strasbourg, Faculté de Médecine, UMRS692, Strasbourg, France; ³Department of Neurology, Ulm University, Ulm, Germany; ⁴Département des Maladies du Système Nerveux, Centre Référent Maladie Rare SLA Hôpital de la Pitié-Salpêtrière (AP-HP); ⁵Université Pierre et Marie Curie, Paris, France
  
  Almost 20 years after the first positive clinical trial, riluzole remains the only drug with proven efficacy in increasing survival in patients with amyotrophic lateral sclerosis (ALS).

  » Read more

  Categories: Neurology

  Teriflunomide for Multiple Sclerosis

  Jiwon Oh, MD, FRCPC^1,2, and Paul W O’Connor, MD, MSc, FRCPC¹

  ¹Department of Neurology, Johns Hopkins University, Baltimore, MD, USA; ²Department of Medicine, Division of Neurology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada.
  
  A number of oral agents are under development and investigation for use in the treatment of multiple sclerosis (MS). Among these experimental agents, teriflunomide is showing promise with respect to safety and clinical efficacy in relapsing MS patients.

  » Read more

  Categories: Neurology